Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
761 to 780 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration. | Front Oncol | 2022 | 36185230 | PubTator, text mining | PubMed |
| Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. | FEBS Open Bio | 2022 | 36176235 | PubTator, text mining | PubMed |
| KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. | Nat Med | 2022 | 36175679 | PubTator, text mining | PubMed |
| Necroptosis-related lncRNA signature predicts prognosis and immune response for cervical squamous cell carcinoma and endocervical adenocarcinomas. | Sci Rep | 2022 | 36175606 | PubTator, text mining | PubMed |
| Comprehensive analysis of ECHDC3 as a potential biomarker and therapeutic target for acute myeloid leukemia: Bioinformatic analysis and experimental verification. | Front Oncol | 2022 | 36172164 | PubTator, text mining | PubMed |
| Construction and Validation of Pyroptosis-Related lncRNA Prediction Model for Colon Adenocarcinoma and Immune Infiltration Analysis. | Dis Markers | 2022 | 36168326 | PubTator, text mining | PubMed |
| Human Papillomavirus-Directed Therapeutics for Human Papillomavirus-Associated Oropharyngeal Cancer. | Cancer J | 2022 | 36165730 | PubTator, text mining | PubMed |
| ABAT gene expression associated with the sensitivity of hypomethylating agents in myelodysplastic syndrome through CXCR4/mTOR signaling. | Cell Death Discov | 2022 | 36163180 | PubTator, text mining | PubMed |
| MJDs family members: Potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma. | Front Genet | 2022 | 36159990 | PubTator, text mining | PubMed |
| Role of B cells as antigen presenting cells. | Front Immunol | 2022 | 36159874 | PubTator, text mining | PubMed |
| Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma. | J Immunol Res | 2022 | 36157883 | PubTator, text mining | PubMed |
| Identification of Novel Immunologic Checkpoint Gene Prognostic Markers for Ovarian Cancer. | J Oncol | 2022 | 36157232 | PubTator, text mining | PubMed |
| The immune subtypes and landscape of sarcomas. | BMC Immunol | 2022 | 36153483 | PubTator, text mining | PubMed |
| Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma. | J Healthc Eng | 2022 | 36147869 | PubTator, text mining | PubMed |
| The Immune Subtypes and Landscape of Advanced-Stage Ovarian Cancer. | Vaccines (Basel) | 2022 | 36146529 | PubTator, text mining | PubMed |
| Proteomic, Metabolomic, and Lipidomic Analyses of Lung Tissue Exposed to Mustard Gas. | Metabolites | 2022 | 36144218 | PubTator, text mining | PubMed |
| A Novel L-Phenylalanine Dipeptide Inhibits the Growth and Metastasis of Prostate Cancer Cells via Targeting DUSP1 and TNFSF9. | Int J Mol Sci | 2022 | 36142828 | PubTator, text mining | PubMed |
| Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma. | Int J Mol Sci | 2022 | 36142223 | PubTator, text mining | PubMed |
| Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations. | Biomedicines | 2022 | 36140243 | PubTator, text mining | PubMed |
| Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise? | Cancers (Basel) | 2022 | 36139598 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=39